CY1117571T1 - Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων - Google Patents

Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων

Info

Publication number
CY1117571T1
CY1117571T1 CY20161100365T CY161100365T CY1117571T1 CY 1117571 T1 CY1117571 T1 CY 1117571T1 CY 20161100365 T CY20161100365 T CY 20161100365T CY 161100365 T CY161100365 T CY 161100365T CY 1117571 T1 CY1117571 T1 CY 1117571T1
Authority
CY
Cyprus
Prior art keywords
clinical
respiratory diseases
rescue
competitive
competition
Prior art date
Application number
CY20161100365T
Other languages
Greek (el)
English (en)
Inventor
Joachim Maus
Beatrix Fyrnys
Torsten Hoffmann
Mario Weingart
Istvan Szelenyi
Peter Jürgen Cnota
Ullrich Munzel
Ursula Petzold
Original Assignee
Meda Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co. Kg filed Critical Meda Pharma Gmbh & Co. Kg
Publication of CY1117571T1 publication Critical patent/CY1117571T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20161100365T 2005-03-16 2016-04-28 Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων CY1117571T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66191805P 2005-03-16 2005-03-16
EP06723360.1A EP1863476B1 (en) 2005-03-16 2006-03-10 The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
CY1117571T1 true CY1117571T1 (el) 2017-04-26

Family

ID=36570797

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100365T CY1117571T1 (el) 2005-03-16 2016-04-28 Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων

Country Status (18)

Country Link
US (1) US8268864B2 (cg-RX-API-DMAC7.html)
EP (1) EP1863476B1 (cg-RX-API-DMAC7.html)
JP (1) JP4991693B2 (cg-RX-API-DMAC7.html)
CN (1) CN101128196B (cg-RX-API-DMAC7.html)
AU (1) AU2006224842B2 (cg-RX-API-DMAC7.html)
CA (1) CA2595791C (cg-RX-API-DMAC7.html)
CY (1) CY1117571T1 (cg-RX-API-DMAC7.html)
DK (1) DK1863476T3 (cg-RX-API-DMAC7.html)
ES (1) ES2570332T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160373T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027076T2 (cg-RX-API-DMAC7.html)
MX (1) MX2007011273A (cg-RX-API-DMAC7.html)
NO (1) NO340405B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ560206A (cg-RX-API-DMAC7.html)
PL (1) PL1863476T3 (cg-RX-API-DMAC7.html)
RU (1) RU2420285C2 (cg-RX-API-DMAC7.html)
SI (1) SI1863476T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006097250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
ES2614090T3 (es) 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
CL2008000468A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Uso de compuestos derivados de heterociclos, inhibidores de leucotrina a4 hidrolasa (lta4h), utiles para tratar o prevenir la dermatitis, acne, infarto al miocardio, dolor, picazon, gingivitis, cancer, artritis, entre otras.
ES2671874T3 (es) 2007-10-18 2018-06-11 Rose U, Llc Formulaciones tópicas de glicopirrolato
NZ584876A (en) * 2007-10-25 2012-06-29 Merck Frosst Canada Ltd Inhalation compositions comprising montelukast acid and a pde-4-inhibitor or an inhaled corticosteroid
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
US9378456B2 (en) * 2012-11-19 2016-06-28 Microsoft Technology Licensing, Llc Task completion
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2981043T3 (es) 2013-02-28 2024-10-07 Journey Medical Corp Procedimiento para fabricar tosilato de glicopirrolato treo
EP2968359B1 (en) * 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
WO2019232306A1 (en) 2018-05-31 2019-12-05 Celtaxsys, Inc. Method of reducing pulmonary exacerbations in respiratory disease patients
JP2022516729A (ja) * 2019-01-10 2022-03-02 ジャンイン ムコケア ファーマシューティカル カンパニー，リミテッド ロイコトリエン受容体アンタゴニストを含有する新たな製剤
NZ790643A (en) * 2020-02-03 2023-05-26 Taro Pharma Ind Topical montelukast formulations
CN115792229B (zh) * 2022-01-28 2024-06-18 华中科技大学同济医学院附属同济医院 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0435038A (ja) * 1990-05-31 1992-02-05 Oki Electric Ind Co Ltd 半導体素子及びその製造方法
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US6204285B1 (en) 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
ES2195121T3 (es) * 1996-11-11 2003-12-01 Christian R Noe Uso de una sal farmaceuticamente aceptable de (3r,2'r)-3-((ciclopentilhidroxifenilacetil)oxi)-1,1-dimetilpirrolidinio para la preparacion de un medicamento.
CA2281789A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
AU7455498A (en) * 1998-05-29 1999-12-20 Citizen Watch Co. Ltd. Method of subjecting ink jet printer to preuse treatment
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US6086914A (en) * 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009583D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
YU33103A (sh) * 2000-10-31 2006-05-25 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Formulacija rastvora za inhalaciju sa soli tiotropijuma
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
ES2292713T3 (es) 2001-03-30 2008-03-16 Jagotec Ag Formulaciones medicinales en aerosol.
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
JP2004530705A (ja) 2001-05-25 2004-10-07 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのｐｄｅ４インヒビター及びチオトロピウム又はその誘導体の組み合わせ
KR20040007605A (ko) 2001-05-25 2004-01-24 화이자 인코포레이티드 폐색성 기도 질환을 치료하기 위한 ｐｄｅ4 억제제 및항콜린제의 복합물
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
MY148466A (en) * 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
US20040038958A1 (en) * 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
AU2003272450A1 (en) * 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
WO2004054556A1 (en) * 2002-12-13 2004-07-01 Adagit Pharmaceutical porous particles
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
EP1610787B1 (en) * 2003-03-28 2008-01-23 Nycomed GmbH Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
JPWO2005055999A1 (ja) 2003-12-08 2007-07-05 日本新薬株式会社 抗コリン作用剤
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1863476B1 (en) 2016-02-03
AU2006224842A1 (en) 2006-09-21
NO20075287L (no) 2007-12-05
EP1863476A1 (en) 2007-12-12
CN101128196A (zh) 2008-02-20
HRP20160373T1 (hr) 2016-05-06
HK1114013A1 (en) 2008-10-24
MX2007011273A (es) 2007-11-08
JP4991693B2 (ja) 2012-08-01
PL1863476T3 (pl) 2016-07-29
DK1863476T3 (en) 2016-05-17
RU2420285C2 (ru) 2011-06-10
WO2006097250A1 (en) 2006-09-21
CA2595791C (en) 2013-10-08
NO340405B1 (no) 2017-04-18
US20060211729A1 (en) 2006-09-21
JP2008533072A (ja) 2008-08-21
AU2006224842B2 (en) 2011-09-29
RU2007138270A (ru) 2009-04-27
NZ560206A (en) 2009-09-25
CN101128196B (zh) 2013-01-02
SI1863476T1 (sl) 2016-05-31
HUE027076T2 (en) 2016-08-29
ES2570332T3 (es) 2016-05-17
US8268864B2 (en) 2012-09-18
CA2595791A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
CY1117571T1 (el) Συνδυασμος αντιχολινεργικων και ανταγωνιστων υποδοχεα λευκοτριενιου για την αγωγη αναπνευστικων νοσηματων
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
NO20063879L (no) Kombinasjonen av antikolinergier og glukokortikoider for langsiktig behandling av astma og KOLS
CY1112968T1 (el) Συνδυασμος αντιχολινεργικων και αναστολεων της φωσφοδιεστερασης τυπου 4 για τη θεραπεια αναπνευστικων νοσων
UY31686A1 (es) Nueva dosificacion y formulacion
CY1110519T1 (el) Συνδυασμος r,r-γλυκοπυρρολικου, ρολιπραμης και βουδεσονιδης για την αντιμετωπιση φλεγμονωδων νοσων
CR8918A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
CY1110373T1 (el) Συνεργιστικος συνδυασμος που περιλαμβανει ροφλουμιλαστη και εναν αντιχολινεργικο παραγοντα που επιλεγεται απο αλατα τιοτροπιου για την θεραπεια αναπνευστικων ασθενειων
ECSP055855A (es) Medicamentos en polvo para inhalación que contiene una sal de tiotropio y salmeterolxinafoato
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
UY31687A1 (es) Nueva dosificacion y formulacion
CY1117758T1 (el) Κουμπι επιστομιου εισπνευστηρα ξηρας κονεως
TR201000623A2 (tr) Yeni tiotropyum kombinasyonu.
NO20081480L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
CY1114364T1 (el) Φαρμακευτικες συνθεσεις για την θεραπεια της αρτηριοπαθειας των τριχοειδων αγγειων
WO2011093820A3 (en) A pharmaceutical combination comprising tiotropium
NO20073909L (no) Forstover-formulering
EA201201389A1 (ru) Ингалятор, создающий турбулентность
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
CY1115266T1 (el) Φαρμακευτικες συνθεσεις αερολυματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.